Lupin Limited (NSE:LUPIN)
India · Delayed Price · Currency is INR 1,984.60
+24.10 (1.23%)
Jul 29, 2025, 3:30 PM IST
Lupin Revenue
In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08B INR with 13.48% growth. Lupin had revenue of 56.67B in the quarter ending March 31, 2025, with 14.24% growth.
Revenue
227.08B
Revenue Growth
+13.48%
P/S Ratio
3.99
Revenue / Employee
9.46M
Employees
24,006
Market Cap
906.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 274.80B |
| Mankind Pharma | 122.07B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.86B |
Lupin News
- 12 days ago - Lupin’s Pithampur Unit-3 gets 3 observations from US FDA after inspection - Business Upturn
- 13 days ago - Lupin launches generic Lotemax ophthalmic suspension in the U.S. market - Business Upturn
- 25 days ago - Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the US market - Business Upturn
- 4 weeks ago - Lupin gets USFDA nod for Loteprednol Etabonate Ophthalmic Gel; Eligible for 180-day generic exclusivity - Business Upturn
- 4 weeks ago - Lupin carves out LupinLife into separate consumer healthcare subsidiary to focus on OTC consumer wellness market - Business Upturn
- 6 weeks ago - Lupin shares in focus as company signs respiratory drug deal in China with Sino Universal - Business Upturn
- 7 weeks ago - Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets - Business Upturn
- 2 months ago - Lupin to present Phase 1 data on LNP7457 cancer drug at ASCO 2025 - Business Upturn